Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors - PubMed (original) (raw)

doi: 10.1016/s1046-2023(02)00220-7.

Mark Potter, Irene Zolotukhin, Yoshihisa Sakai, Scott Loiler, Thomas J Fraites Jr, Vince A Chiodo, Tina Phillipsberg, Nicholas Muzyczka, William W Hauswirth, Terance R Flotte, Barry J Byrne, Richard O Snyder

Affiliations

• PMID: 12413414
• DOI: 10.1016/s1046-2023(02)00220-7

Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors

Sergei Zolotukhin et al. Methods. 2002 Oct.

Abstract

Recombinant adeno-associated viral (rAAV) vectors based on serotype 2 are currently being evaluated most extensively in animals and human clinical trials. rAAV vectors constructed from other AAV serotypes (serotypes 1, 3, 4, 5, and 6) can transduce certain tissues more efficiently and with different specificity than rAAV2 vectors in animal models. Here, we describe reagents and methods for the production and purification of AAV2 inverted terminal repeat-containing vectors pseudotyped with AAV1 or AAV5 capsids. To facilitate pseudotyping, AAV2rep/AAV1cap and AAV2rep/AAV5cap helper plasmids were constructed in an adenoviral plasmid backbone. The resultant plasmids, pXYZ1 and pXYZ5, were used to produce rAAV1 and rAAV5 vectors, respectively, by transient transfection. Since neither AAV5 nor AAV1 binds to the heparin affinity chromatography resin used to purify rAAV2 vectors, purification protocols were developed based on anion-exchange chromatography. The purified vector stocks are 99% pure with titers of 1 x 10(12) to 1 x 10(13)vector genomes/ml.

Copyright 2002 Elsevier Science (USA)

PubMed Disclaimer

Similar articles

• Transduction of pancreatic islets with pseudotyped adeno-associated virus: effect of viral capsid and genome conversion.
  Zhang N, Clément N, Chen D, Fu S, Zhang H, Rebollo P, Linden RM, Bromberg JS. Zhang N, et al. Transplantation. 2005 Sep 15;80(5):683-90. doi: 10.1097/01.tp.0000173381.97556.0d. Transplantation. 2005. PMID: 16177645
• Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors.
  Chen S, Kapturczak M, Loiler SA, Zolotukhin S, Glushakova OY, Madsen KM, Samulski RJ, Hauswirth WW, Campbell-Thompson M, Berns KI, Flotte TR, Atkinson MA, Tisher CC, Agarwal A. Chen S, et al. Hum Gene Ther. 2005 Feb;16(2):235-47. doi: 10.1089/hum.2005.16.235. Hum Gene Ther. 2005. PMID: 15761263 Free PMC article.
• Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system.
  Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier PJ, Mandel RJ, Muzyczka N. Burger C, et al. Mol Ther. 2004 Aug;10(2):302-17. doi: 10.1016/j.ymthe.2004.05.024. Mol Ther. 2004. PMID: 15294177
• Production methods for gene transfer vectors based on adeno-associated virus serotypes.
  Grimm D. Grimm D. Methods. 2002 Oct;28(2):146-57. doi: 10.1016/s1046-2023(02)00219-0. Methods. 2002. PMID: 12413413 Review.
• Production of clinical-grade recombinant adeno-associated virus vectors.
  Snyder RO, Flotte TR. Snyder RO, et al. Curr Opin Biotechnol. 2002 Oct;13(5):418-23. doi: 10.1016/s0958-1669(02)00369-5. Curr Opin Biotechnol. 2002. PMID: 12459331 Review.

Cited by

• A simplified purification protocol for recombinant adeno-associated virus vectors.
  Potter M, Lins B, Mietzsch M, Heilbronn R, Van Vliet K, Chipman P, Agbandje-McKenna M, Cleaver BD, Clément N, Byrne BJ, Zolotukhin S. Potter M, et al. Mol Ther Methods Clin Dev. 2014 Aug 13;1:14034. doi: 10.1038/mtm.2014.34. eCollection 2014. Mol Ther Methods Clin Dev. 2014. PMID: 26015974 Free PMC article.
• Intracellular FGF14 (iFGF14) Is Required for Spontaneous and Evoked Firing in Cerebellar Purkinje Neurons and for Motor Coordination and Balance.
  Bosch MK, Carrasquillo Y, Ransdell JL, Kanakamedala A, Ornitz DM, Nerbonne JM. Bosch MK, et al. J Neurosci. 2015 Apr 29;35(17):6752-69. doi: 10.1523/JNEUROSCI.2663-14.2015. J Neurosci. 2015. PMID: 25926453 Free PMC article.
• Cholecystokinin knock-down in the basolateral amygdala has anxiolytic and antidepressant-like effects in mice.
  Del Boca C, Lutz PE, Le Merrer J, Koebel P, Kieffer BL. Del Boca C, et al. Neuroscience. 2012 Aug 30;218:185-95. doi: 10.1016/j.neuroscience.2012.05.022. Epub 2012 May 18. Neuroscience. 2012. PMID: 22613736 Free PMC article.
• Benefits of Neuronal Preferential Systemic Gene Therapy for Neurotransmitter Deficiency.
  Lee NC, Muramatsu S, Chien YH, Liu WS, Wang WH, Cheng CH, Hu MK, Chen PW, Tzen KY, Byrne BJ, Hwu WL. Lee NC, et al. Mol Ther. 2015 Oct;23(10):1572-81. doi: 10.1038/mt.2015.122. Epub 2015 Jul 3. Mol Ther. 2015. PMID: 26137853 Free PMC article.
• Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus.
  Lopes VS, Boye SE, Louie CM, Boye S, Dyka F, Chiodo V, Fofo H, Hauswirth WW, Williams DS. Lopes VS, et al. Gene Ther. 2013 Aug;20(8):824-33. doi: 10.1038/gt.2013.3. Epub 2013 Jan 24. Gene Ther. 2013. PMID: 23344065 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information